Two Wolves, One Vendor Spreadsheet

The cardio wolf loses every night at 2:14 AM to the wolf with 47 tabs open ranking vendor COAs by purity percentage.

Filed under Retatrutide ·Cagrilintide ·Survodutide · #stack-life ·#cope ·#vendor-discourse

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

RX: Retatrutide · Cagrilintide · Survodutide
Dosage: 47 tabs
Half-life: until sunrise
Source: manual
Tags: stack-life , cope , vendor-discourse
Stamped: 2026-05-29 · Cycle 022
Lot #: LOT-20260529T11:14:19.910Z